Christopher Mann

About Christopher Mann

I am a scientific professional with a foundation in analytical chemistry and a natural aptitude for problem-solving, strategic thinking, and data interpretation. With nine years of experience in analytical development and CMC, I specialize in leveraging advanced analytical instrumentation to support drug discovery, process development, and regulatory compliance for both small molecules and biologics. My expertise lies in troubleshooting complex technical challenges, optimizing methodologies, and implementing innovative solutions that enhance efficiency and precision. I actively explore emerging technologies to drive advancements in therapeutic development, ensuring alignment with regulatory and industry best practices. Beyond technical proficiency, I thrive in fast-paced, multidisciplinary environments, working closely with R&D, quality, regulatory, and external partners to achieve shared objectives. I have experience translating complex scientific data into actionable insights, preparing scientific reports, regulatory filings, and strategic presentations that support decision-making and compliance. I am driven by the intersection of science and strategy, combining analytical expertise with business-minded problem-solving to foster strong collaborations, streamline processes, and contribute to industry advancements. As I expand my focus into business development, I aim to bridge technical insight with commercial strategy, helping biotech and pharmaceutical partners navigate the challenges of drug development and bring innovative therapies to market.

Experience

1. Principal Associate

   Bavarian Nordic

   Jul 2022 — Present · San Diego, CA, US

   Acquired expertise in Waters Empower and Acquity UPLC within four weeks, enabling timely and accurate analytical testing and reducing analytical capabilities testing gaps.• Enhanced an HPLC-based glycan assay’s recovery to ensure a coefficient of variance below 20%, significantly improving the assay’s reliability to measure a Critical Quality Attribute.• Drafted a physical viral titer assay by Field Flow Fractionation coupled with Multi Angle Light Scattering detection to significantly reduce both time and cost for measuring this Critical Quality Attribute in support of viral production.• Quantified a previously unknown attribute related to viral particle heterogeneity by Charge Detection Mass Spectrometry (CDMS) to de-risk FDA likely feedback.• Qualified a non-clinical Enzyme-Linked Immunosorbent Assay (ELISA) testing protocol for IgG quantification in Non-Human Primates through collaboration with a biostatistician.• Investigated comprehensive internal reports and available literature to draft a testing protocol for an Enzyme-Linked Immunosorbent Spot (ELISPOT) assay for testing of non-clinical Non-Human Primate Peripheral Blood Mononuclear Cells (PBMCs).• Presented analytical data to guide project decisions, partnering with partnering with Research & Development, Quality Control, Quality Assurance, and regulatory teams.• Drafted and revised Standard Operating Procedures (SOPs) for analytical methods, ensuring consistency with FDA and ICH guidelines with the Veeva Quality Management System.• Conducted sample testing in compliance with cGLP guidelines in the Veeva Quality Management System.

Education

• Penn State University

  Bachelor of Science (B.S.)

  2009 — 2014

• Penn State University

  Master's Degree

  2014 — 2015